Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 15/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 9/20 | 0.55 |
| ▸ | PER2 | O15055 | 1/20 | 0.35 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.35 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20246096 | 0.70 | FFAR4 (0.54) | FFAR4FFAR1CACNA1H | |
| SCHEMBL31069628 | 0.69 | FFAR4 (0.47) | FFAR4FFAR1CACNA1H | |
| SCHEMBL20099012 | 0.68 | FFAR4 (0.52) | FFAR4FFAR1 | |
| SCHEMBL23732663 | 0.68 | FFAR4 (0.45) | FFAR4FFAR1PER2CRY1CRY2 | |
| SCHEMBL19967183 | 0.68 | ESR1 (0.53) | FFAR4FFAR1PTPN1 | |
| SCHEMBL19967184 | 0.68 | FFAR4 (0.52) | FFAR4FFAR1CACNA1HPTPN1SLC40A1 | |
| SCHEMBL8157650 | 0.67 | BRD4 (0.50) | FFAR4FFAR1PER2CRY1CRY2 | |
| SCHEMBL28194834 | 0.67 | FFAR4 (0.44) | FFAR4FFAR1PER2CRY1CRY2 | |
| SCHEMBL19673967 | 0.67 | FFAR4 (0.44) | FFAR4FFAR1PER2CRY1CRY2 | |
| SCHEMBL28207011 | 0.67 | FFAR4 (0.44) | FFAR4FFAR1PER2CRY1CRY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090136448-A1 | Antiviral 2-Carboxy-Thiophene Compounds | CORFIELD JOHN ANDREW | 2009-05-28 | — | — | US | disclosed |
| EP-1971599-A1 | ANTIVIRAL 2-CARBOXY-THIOPHENE COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-09-24 | — | — | EP | disclosed |
| WO-2007088148-A1 | DERIVATIVES OF THIOPHENE CARBOXILIC ACID AS ANTIVIRAL AGENT | SMITHKLINE BEECHAM CORPORATION (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007071434-A1 | ANTIVIRAL 2-CARBOXY-THIOPHENE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007039146-A1 | 4-CARBOXY PYRAZOLE DERIVATIVES AS ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090136448-A1 | Antiviral 2-Carboxy-Thiophene Compounds | EIF2AK2, HAVCR2, MAVS | FFAR4 3792/4885FFAR1 3634/4885PER2 2807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.